IGRA sil oqsillariga immunitet javobini o'lchaydi, sil bakteriyalari hozirda kasallikni keltirib chiqarayotganligini aniqlamaydi. Kategoriya muhim, ammo ta'sirlanish tarixi, alomatlar va immunitet holati keyingi qadamni belgilaydi.
- Ijobiy IGRA immunitet hujayralari silga xos oqsillarni tan olganligini anglatadi; bu faol silni isbotlamaydi yoki ta'sirlanish qachon sodir bo'lganligini aytmaydi.
- QuantiFERON ijobiy chegarasi odatda TB1-Nil yoki TB2-Nil kamida 0,35 IU/mL va Nil qiymatining kamida 25% ni tashkil qiladi.
- T-SPOT.TB ijobiy chegarasi odatda Nil nazoratidan 8 yoki undan ortiq antigen nuqtalari; 5–7 nuqta ba'zi laboratoriyalarda chegaradagi deb hisoblanishi mumkin.
- Salbiy IGRA faqat Mitogen nazorati etarli darajada javob berganda va ta'sirlanish oxirgi 8 hafta ichida bo'lmaganida sil infektsiyasini kamroq ehtimol qiladi.
- Belgilanmagan IGRA natijasi nazoratlar ishlamay qolganini bildiradi, ko'pincha yuqori fon signali yoki zaif immunitet javobi tufayli, balki ijobiy yoki salbiy sil javobidan ko'ra.
- BCG vaktsinasi odatda ijobiy IGRA ni keltirib chiqarmaydi, chunki IGRA antigenlari ESAT-6 va CFP-10 BCG vaktsina shtammlarida mavjud emas.
- Faol silni istisno qilish simptomlarni ko'rib chiqish, ko'krak qafasi tasvirini tekshirish va mikrobiologiya testini talab qiladi; na IGRA, na sil terisi testi faol infeksiyani latent infeksiyadan ajrata olmaydi.
- Shoshilinch belgilar qon bilan yo'talish, nafas qisilishining kuchayishi, doimiy isitma, tunlari terlash yoki sababsiz vazn yo'qotish; bir xil kunlik tibbiy tekshiruvni talab qilish.
Har bir IGRA toifasi sodda tilda nimani anglatadi
IGRA testi natijalari ijobiy, salbiy yoki aniqlanmagan deb xabar qilinadi. Ijobiy natija sil infeksiyasini tasdiqlaydi, salbiy natija uning ehtimolini kamaytiradi va aniqlanmagan natija laboratoriya nazoratlarining talqin qilishga imkon bermaganligini bildiradi; ushbu uchta toifaning hech biri yolg'iz faol silni tashxislashga qodir emas.
Test amalga oshiriladi laboratoriya namunasi tirik oq hujayralarni o'z ichiga olgan, ular tanlangan Mycobacterium tuberculosis oqsillariga duchor bo'ladi. Agar sezgir T hujayralari interferon-gamm a ajratsa, tahlil ijobiy bo'ladi. Kantesti bu AI qon testi analizatori yuklangan IGRA hisobotini uning ko'rsatilgan nazoratlari, birliklari va boshqa laboratoriya topilmalari bilan bir qatorda joylashtira oladigan, lekin sil faolligini faqat natija toifasidan aniqlay olmaydigan vositadir.
Natija xavf reytingi emas. 0,36 IU/mL QuantiFERON qiymati texnik jihatdan ijobiy bo'lishi mumkin, ammo u odatdagi 0,35 IU/mL chegarasidan biroz yuqoriroq turadi va 8,0 IU/mL natijasidan ko'ra ta'sir ehtimoliga ko'proq e'tibor qaratishga arziydi. Tomas Keyn sifatida, men bemor “ijobiy” degan so'zni yuqumli kasallikka tenglashtirganda keraksiz vahima ko'rdim.
2017 ATS/CDC/IDSA diagnostika qo'llanmasida aytilishicha, IGRA va sil terisi testi sil infeksiyasini aniqlaydi, ammo latent infeksiyani faol kasallikdan ajrata olmaydi (Lewinsohn et al., 2017). Bu farq klinik jihatdan, odatda simptomlarni skrining qilish, ko'krak qafasi rentgenogrammasi va talab qilinadigan joylarda nafas olish namunalari bilan amalga oshiriladi. Bizning ijobiy antikor natijasi uchun qo'llanmamiz immunitetni tanib olish testlari uchun shu bir xil kontekstga nima uchun kerakligini tushuntiradi.
QuantiFERON va T-SPOT sil immunitetini qanday o'lchaydi
IGRA lar aniqlaydi T limfotsitlari tomonidan ajratilgan interferon-gamm a silga xos antigenlar bilan stimulyatsiya qilingandan keyin. QuantiFERON interferon-gamm a konsentratsiyasini IU/mL da o'lchaydi, T-SPOT.TB esa javob beruvchi hujayrali nuqtalarni hisoblaydi; ularning natijasi formatlari almashtirilmaydi.
QuantiFERON-TB Gold Plus ikkita antigen naychasidan, TB1 va TB2, shuningdek, Nil fon naychasidan va Mitogen ijobiy-nazorat naychasidan foydalanadi. Odatdagi ijobiy mezon TB1-Nil yoki TB2-Nil hech bo'lmaganda 0,35 IU/mL va kamida Nil dan 25%. Mitogen nazorati odatda ishonchli salbiy tahlil uchun Nil dan kamida 0,50 IU/mL yuqoriroq natija berishi kerak.
T-SPOT.TB har bir quduqchaga joylashtirilgan periferik qon mononuklear hujayralarining sonini standartlashtiradi, keyin interferon-gamm a ishlab chiqaruvchi hujayralarni nuqtalar sifatida hisoblaydi. Odatda ishlatiladigan talqin mezonlarida, 8 yoki undan ko'p nuqta Nil dan yuqori ijobiy, 5–7 nuqta chegarada, va 4 yoki undan kam salbiy, nazoratlar to'g'ri bo'lsa. Laboratoriyalar mintaqaga xos hisobot tilidan foydalanishi mumkin, shuning uchun laboratoriyaning o'ziga xos ma'lumotnomalarini o'qing.
Juda yuqori Nil nazorati haqiqiy signalni yashirishi mumkin, yaxshi bo'lmagan Mitogen javobi esa hujayralar keng stimulyatorga ham javob bermaganligini ko'rsatadi. Shuning uchun ikkilik ko'rinadigan hisobotda tekshirishga arziydigan sifat nazorati ma'lumotlari mavjud. Namuna va tahlil atamashunosligini kengroq tushuntirish uchun bizning sarumga qarshi plazma qo'llanmamizga.
Ijobiy IGRA testi odatda nimani anglatadi
A ijobiy IGRA testi ma'nosi shundaki, sizning immunitet tizimingiz ilgari Mycobacterium tuberculosis bilan bog'liq oqsillarni tanigan. Bu sil infektsiyasini qo'llab-quvvatlaydi, lekin u infektsiyaning sanasini, joyini, og'irligini yoki joriy faolligini aniqlamaydi.
Ijobiy natijalar eng yaqin uy ta'siridan, tug'ilishdan yoki yuqori darajadagi joyda uzoq muddat yashashdan keyin yoki immunitetni bostiruvchi terapiyadan oldin eng ko'p klinik jihatdan ishonchlidir. Ta'sir qilish ehtimoli deyarli yo'q bo'lgan shaxsda 0,35 IU/mL ga yaqin past darajadagi natija shu natijaning uy kontaktidagi natijasidan pastroq ijobiy bashorat qiymatiga ega. Testdan oldingi ehtimollik har bir skrining testining ma'nosini o'zgartiradi.
Interferon-gamma kontsentratsiyasi ham, nuqta soni ham bakterial yukni o'lchamaydi. 4,5 IU/mL natijasi 0,5 IU/mL dan “ko'proq yuqumli” degani emas, va faol o'pka sil kasalligi bo'lgan bemorda o'rtacha ijobiy qiymat bo'lishi mumkin. Mening klinik tajribamda raqamli ortiqcha o'qish IGRA hisobotidan keyin eng ko'p uchraydigan tashvish manbalaridan biridir.
Ijobiy testdan oldin tibbiy tarix, tekshiruv va ko'krak qafasi tasvirlari silga qarshi davolashni muhokama qilishdan oldin amalga oshirilishi kerak. 2-3 hafta davom etadigan yo'tal, isitma, tungi terlash yoki ixtiyorsiz vazn yo'qotish kabi alomatlar darhol yo'nalishni o'zgartiradi. Agar umumiy qon tahlili ham mavjud bo'lsa, bizning limfotsitlar diapazoni bo'yicha tushuntirish silni baholash o'rnini bosmasdan, immunitet hujayralari kontekstini shakllantirishga yordam beradi.
Nega ijobiy natija latent silni faol sildan ajrata olmaydi
Ijobiy IGRA latent sil infektsiyasi va faol sil kasalligini farqlay olmaydi chunki ikkala holatda ham sil antigenlarini tan oladigan T hujayralari qonda aylanishi mumkin. Ushbu cheklov interferon-gamma qiymati juda yuqori bo'lsa ham amal qiladi.
Latent sil infektsiyasi deganda simptomlar, radiografik dalillar yoki faol kasallikning mikrobiologik dalillarisiz infektsiyaning immunitet dalillari tushuniladi. Faol sil kasalligi deganda bakteriyalar kasallikni keltirib chiqaradi va ayniqsa o'pkalar yoki nafas yo'llari jalb qilinganida yuqumli bo'lishi mumkin. IGRA ikkala holatda ham mavjud bo'lgan mezbonning javobini aniqlaydi, ma'lum bir organdagi bakteriyalarni emas.
Ko'krak qafasi rentgenografiyasi odatda asemptomatik shaxsda ijobiy IGRA dan keyin birinchi istisno bosqichidir. Anormal tasvir, nafas olish belgilari yoki OIV bilan bog'liq immunitetning buzilishi odatda balg'am nuklein kislota amplifikatsiyasi testi, surtma mikroskopiyasi va madaniyatni talab qiladi; madaniyat bir necha hafta davom etishi mumkin, ammo dori sezgirligi haqida ma'lumot beradi. Normal ko'krak qafasi rentgenogrammasi o'pka kasalligi haqidagi xavotirni kamaytiradi, lekin silning har qanday shaklini to'liq istisno qilmaydi.
Silni tashxislash bo'yicha JSST ko'rsatmalari ham kattalardagi faol kasallikni tashxislash uchun IGRA yoki TST dan foydalanishga qarshi ogohlantiradi (Jahon Sog'liqni Saqlash Tashkiloti, 2021). Davomiy yo'tal va ijobiy IGRA bir kunlik klinik muammo, ilova talqini mashqi emas. Bizning nafas qisishi qon testi qo'llanmasini ko'ring. respirator simptomlar bilan birga bo'lishi mumkin bo'lgan boshqa shoshilinch laboratoriya kontekst signallari uchun ko'rib chiqing.
Salbiy IGRA qachon tasalli beradi — va qachon bermaydi
A salbiy IGRA sil antigenlari nazoratlar to'g'ri ishlagan holda tegishli interferon-gamma javobini bermaganligini bildiradi. Bu sil infektsiyasini kamroq ehtimol qiladi, lekin u juda yaqinda yuqishni, faol silni yoki immunitetni bostirishni ishonchli tarzda istisno qilmaydi.
Immunitet tizimiga kerak bo'lishi mumkin 2 dan 8 haftagacha ani aniq javobni rivojlantirish uchun ta'sir qilishdan keyin. CDC yaqin aloqa uchun oxirgi ta'sirdan keyin takroriy IGRA ni tavsiya qiladi 8 dan 10 haftagacha chunki dastlabki oynada bajarilgan test yolg'on manfiy bo'lishi mumkin (Mazurek et al., 2010). 3-kundan olingan salbiy test yakuniy tozalash natijasi emas.
O'ta rivojlangan OIV, kimyoterapiya, organ transplantatsiyasi, yuqori dozali kortikosteroidlar va og'ir o'tkir kasallik T-hujayralarining javobini kamaytirishi mumkin. Prednizolon dozalari kuniga 15 mg yoki undan ko'p, 1 oy davomida ko'pincha TB xavfi baholanayotganida klinik jihatdan ahamiyatli immunitet tanqisligi sifatida qaraladi, garchi har qanday individual tahlilga aniq ta'siri o'zgarib tursa ham. Ushbu sharoitlarda salbiy test natijasi mutaxassislar tomonidan baholanishni talab qiladi.
Kantesti AI yuklangan hisobotda “salbiy”ni umumiy tasalli sifatida qabul qilishdan ko'ra, haqiqiy Mitogen nazoratini ko'rsatadimi, shuni ko'rsatadi. Bu bizning immunitet tizimi testi haqida umumiy ma'lumot immunitet yoki dori-darmonlar tarixi oddiy natijani murakkablashtirganda foydalidir.
Belgilangan IGRA natijasini nima keltirib chiqaradi
An aniqlanmagan IGRA natijasi bu bajarilmagan test sifati natijasi, TB infektsiyasi uchun yoki unga qarshi dalil emas. QuantiFERON testida bu ko'pincha 0,50 IU/mL dan past Mitogen-Nil qiymati yoki 8,0 IU/mL dan yuqori Nil qiymati natijasida yuzaga keladi.
Zaif Mitogen javobi namunaning limfotsitlari kutilgan keng immunitet javobini ko'rsatmaganligini anglatadi. Bu limfopeniya, og'ir kasallik, immunitetni bostiruvchi dorilar, namunalarni kechiktirib inkubatsiya qilish yoki oddiy preklinik ishlov berish muammolari bilan yuzaga kelishi mumkin. Bu odamda TB borligini bildirmaydi va bu ijobiy skrining sifatida qayd etilmasligi kerak.
Yuqori Nil javobi TB antigenlari qo'shilishidan oldin fon gamma-interferoni allaqachon yuqori bo'lganligini anglatadi. Autoimmun faollik, boshqa infektsiya, laboratoriya ishlov berish va ba'zan tushunilmagan biologik o'zgarishlar bunga hissa qo'shishi mumkin. T-SPOT.TB tahlilida haddan tashqari yuqori Nil nuqtalari yoki etarli bo'lmagan ijobiy nazorat nuqtalari o'rniga yaroqsiz deb hisoblanishi mumkin.
Vaqtinchalik kasallik tuzalgach, ideal holda ehtiyotkorlik bilan yig'ish va tez laboratoriya transporti bilan takroriy test o'tkazish mantiqiy. Kantesti bu AI lab test interpretatsiya xizmati hisobotda aniqlangan Nil yoki Mitogen nazoratining bajarilmasligini aniqlay oladi, shu bilan birga buyurtmachi shifokor IGRA, TST yoki faol TB tekshiruvini takrorlash maqsadga muvofiqligini hal qiladi. Bizning maqolamiz laboratoriya xatosi tufayli qayta tekshirish namuna sifati natijalarni qanday o'zgartirishi mumkinligini tushuntiradi.
BCG vaktsinasi nega IGRA natijalariga kamdan-kam ta'sir qiladi
BCG vaktsinasi odatda ijobiy IGRA ni keltirib chiqarmaydi chunki standart IGRA lar BCG vaktsina shtammlarida mavjud bo'lmagan ESAT-6 va CFP-10 antigenlaridan foydalanadi. Bu BCG bilan emlangan odamlarda IGRA ning TB terini sinashdan ustunligi.
Tuberculin terini sinash toza protein hosilasidan foydalanadi, bu BCG va ko'plab atrof-muhit mikobakteriyalari bilan kesishadigan keng aralashma. IGRA antigenini tanlash bu kesishuv reaktivligini toraytirish uchun ishlab chiqilgan. Kantesti bu AI qon tahlili natijalari platformasi natijani yuklaganida ushbu BCG farqini tushuntiradi, ammo hisobot hali ham ta'sir qilish va alomatlar kontekstini talab qiladi.
Bilishga arziydigan istisnolar mavjud. ESAT-6 va CFP-10 kichik bir guruh tuberkulyoz bo'lmagan mikobakteriyalarda, xususan M. kansasii, M. marinum va M. szulgai da uchraydi, so infection with these organisms can occasionally produce a positive IGRA. This is uncommon but matters in people with aquarium exposure, certain occupational exposures or compatible lung disease.
BCG may still matter when interpreting an old skin-test record, especially if vaccination occurred after infancy or was repeated. A positive IGRA in someone vaccinated at birth should not be dismissed as “just BCG.” For a broader look at interpreting immune test positives, see our ANA test results guide.
IGRA testi va sil terisi testi: to'g'ri testni tanlash
Homiladorlikdagi nozik jihat IGRA test vs TB skin test comparison, IGRA is often preferred for BCG-vaccinated adults and people unlikely to return for skin-test reading. The skin test remains useful where IGRA is unavailable, cost-prohibitive or locally recommended.
An IGRA requires one sample collection and laboratory processing, while a tuberculin skin test must be measured 48 dan 72 soatgacha after placement. Missing that reading window makes the skin test unusable. The skin test can also boost subsequent tests in serial screening, a phenomenon less relevant to IGRA.
Neither option is a general population screening test in low-risk adults. US and UK guidance generally favors targeted testing of people with exposure, migration-related risk, occupational risk or planned immunosuppression because false positives become more likely as baseline risk falls. Testing without a reason can create a cascade of avoidable imaging and anxiety.
For children younger than 5 years, practices differ by country and service; some clinicians prefer a skin test because paediatric IGRA data are less consistent and sample handling can be harder. The children’s lab interpretation guide explains why adult thresholds and reports cannot simply be transplanted into paediatric care.
Vaqt, chegaradagi qiymatlar va o'zgaruvchan IGRA natijalari
IGRA values close to the assay cutoff can change category on repeat testing because of normal biological and laboratory variation. A new result just above 0.35 IU/mL should be interpreted with exposure timing and absolute risk, not treated as a precise measure of infection severity.
For a close contact, test once promptly to establish a baseline and repeat 8–10 weeks after the last exposure if the first test is negative. A positive test during this interval warrants active-disease assessment immediately; one does not wait for the later test. This approach catches delayed immune conversion without delaying safety evaluation.
Some laboratories describe a borderline zone for QuantiFERON research or local occupational policies, often around 0.20–0.70 IU/mL, but this is not a universal manufacturer diagnostic category. T-SPOT.TB has a formal borderline category in many settings at 5–7 spots. Clinicians disagree on automatic retesting thresholds because patient risk often matters more than a narrow numerical band.
Serial testing in healthcare workers has produced apparent conversions and reversions near the cutoff even without known exposure. Recording the assay brand, Nil, TB1, TB2 and Mitogen values is far more useful than saving only “positive” or “negative.” Our lab-results timeline guide shows what to preserve before a repeat test.
IGRA natijasidan keyin kim tezroq tekshiruvdan o'tishi kerak
People with a positive IGRA need faster follow-up when they have TB symptoms, close exposure, HIV, immune-suppressing treatment or a planned TNF-inhibitor or transplant regimen. A positive result in an otherwise well, low-risk person is usually urgent in days rather than minutes, but should not be ignored.
Highest-priority groups include household contacts of contagious pulmonary TB, people with HIV, recipients of solid-organ or stem-cell transplants, and those starting anti-TNF treatment. Risk of progression is greatest soon after infection and when cellular immunity is impaired. A chest radiograph is generally obtained before preventive therapy to avoid missing active disease.
Pregnancy does not itself make an IGRA positive or negative, but symptoms, HIV status and exposure history still matter. In a pregnant person with exposure and symptoms, investigation for active TB should proceed without waiting for delivery. Preventive-treatment timing depends on the risk profile and local obstetric-TB expertise.
Dr. Thomas Klein’s practical advice is to bring the full report and a dated exposure timeline to the appointment, not a cropped portal screenshot. The sog‘liq tarixi kuzatuvchisi can help retain dates, medicines and previous imaging that meaningfully affect this decision.
Faol silni tekshirishni talab qiladigan alomatlar
A positive or negative IGRA does not overrule symptoms suggestive of active TB. Cough lasting 2–3 weeks, haemoptysis, persistent fever, drenching night sweats, chest pain, unexplained weight loss or worsening shortness of breath require prompt in-person evaluation.
Active pulmonary TB is assessed with a focused history, examination, chest radiograph and respiratory microbiology. Sputum nucleic-acid amplification can provide a rapid TB signal, while culture confirms disease and identifies susceptibility patterns. If sputum cannot be produced, clinicians may use induced sputum or bronchoscopy depending on severity and imaging findings.
A normal IGRA can occur in active TB, particularly in severe disease or impaired immunity. Conversely, a positive result can remain after successful treatment and should not be used to monitor whether treatment worked. Symptom change, imaging and microbiology are the appropriate markers of response.
Do not self-start antibiotics left over from another illness; partial treatment can complicate microbiological diagnosis. A raised inflammatory marker is non-specific, as discussed in our yuqori ESR sabablariga oid qo‘llanmada solishtirishi mumkin, and cannot confirm or exclude TB.
Bolalar, homiladorlik va immunitet tanqisligida IGRA talqini
IGRA interpretation is less reliable when T-cell function is impaired or sample handling is difficult. Young children, people with advanced HIV, patients receiving chemotherapy or high-dose steroids, and those who are acutely unwell have higher rates of false-negative or indeterminate results.
In children under 5 years, clinicians may use a skin test, IGRA or both according to local public-health guidance and exposure severity. A well child with a negative early test after a household exposure may still need repeat testing at 8–10 weeks. Infant and child contact management should be directed by paediatric or TB services, not delayed for an app result.
Anti-TNF medicines, JAK inhibitors, methotrexate, calcineurin inhibitors and systemic corticosteroids can affect TB risk and test responsiveness. Screening is best done before immune suppression begins whenever practical. If treatment cannot wait, specialists may use exposure history, imaging and dual-test strategies rather than relying on one negative result.
Kantesti - bu AI asosidagi qon tahlili analiz vositasi that can organize medication lists and related results around an IGRA report, but it does not determine whether preventive therapy is safe. For medication-linked trend review, our blood-test trend article explains the records clinicians actually need.
Hisobotingizdagi raqamlar va nazoratlarni qanday o'qish kerak
The most useful IGRA report includes assay name, collection date, antigen values, Nil value, Mitogen result and final laboratory interpretation. The final word alone hides whether a result was near a threshold or whether controls were weak.
For QuantiFERON, look for Nil, TB1-Nil, TB2-Nil va Mitogen-Nil. A TB1-Nil of 0.34 IU/mL is generally negative by the standard 0.35 IU/mL cutoff, but its practical meaning differs sharply between an asymptomatic low-risk worker and a recent household contact. The laboratory may also flag values outside the reportable range.
For T-SPOT.TB, locate the Nil spots, Panel A spots, Panel B spots and positive-control result. A result of 6 spots may be called borderline rather than negative, so follow-up often depends on exposure and local protocol. Never compare spot counts directly with QuantiFERON IU/mL values; they measure different analytical endpoints.
Kantesti AI interprets IGRA report components by keeping the assay methodology, controls and stated laboratory category together rather than converting a qualitative result into a diagnosis. Readers can review our AI hisobot aniqligi bo‘yicha chek-listimizdan foydalaning. va texnologiya qo‘llanmasi to understand those safety boundaries.
Ijobiy, salbiy yoki belgilanmagan natijalardan keyingi amaliy qadamlar
After a positive IGRA, arrange clinical review and active-TB exclusion; after a valid negative test, repeat only if exposure was recent or risk remains high; after an indeterminate result, investigate control failure and usually repeat. The correct next step is determined by risk, symptoms and timing—not by the category alone.
Bring these five details to your appointment: the entire result report, date of last possible exposure, BCG history, current medicines and any symptoms. If active disease is excluded and latent infection is diagnosed, treatment options commonly include 3 months of weekly isoniazid plus rifapentine, 4 months of rifampicin, or other local protocols; regimen choice depends on drug interactions and country guidance.
Rifampicin and rifapentine can substantially reduce the effectiveness of hormonal contraception and interact with anticoagulants, antiretrovirals and transplant medicines. Baseline liver tests may be considered, especially with liver disease, alcohol use, pregnancy-related risk or interacting medicines; a single mildly abnormal ALT does not automatically rule out treatment. Our jigar tahlili qisqartmalari qo'llanmasi explains the usual panel components.
As of September 15, 2026, no consumer interpretation tool replaces a TB clinician’s decision to investigate infectious disease. Kantesti’s physician oversight and clinical standards are described by our Tibbiy maslahat kengashi va tibbiy validatsiya jarayonimiz orqali ko‘rib chiqiladi.; use an uploaded report to prepare better questions, not to defer care.
Tez-tez so'raladigan savollar
IGR testining ijobiy natijasi silning faol ekanligini bildira oladimi?
IGRAnıng musbat natijasi immunitet hujayralari silga xos antigenlarni tan olganini tasdiqlaydi, lekin bu infeksiya latent yoki faol ekanligini ayta olmaydi. Faol silni baholash uchun simptomlar, ko'krak qafasi tasvirlari va zarur bo'lganda nafas yo'llarining nuklein kislota sinovi va madaniyatni tekshirish talab qilinadi. 0,35 IU/mL dan yuqori QuantiFERON qiymati infektsiyalilikni o'lchash emas, balki immunitet javobining musbat chegarasidir. 2-3 hafta davom etadigan yo'tal, isitma, tungi terlama, vazn yo'qotish yoki qonli yo'tal bo'lgan har bir kishi zudlik bilan klinik baholashdan o'tishi kerak.
BCG vaksinatsiyasi IGRA natijasining ijobiy chiqishiga sabab bo'ladimi?
BCG vaksinasi odatda ijobiy IGRA hosil qilmaydi, chunki standart tahlillar BCG vaktsina shtammlari tarkibida bo'lmagan ESAT-6 va CFP-10 antigenlaridan foydalanadi. Bu TB terini tekshirishdan farq qiladi, u BCG dan keyin ijobiy bo'lishi mumkin, chunki u kengroq tozalanmagan oqsil hosilasidan foydalanadi. M. kansasii, M. marinum yoki M. szulgai infektsiyasi bilan kamdan-kam hollarda o'zaro reaksiyaga kirishish mumkin. Tug'ilganda BCG bilan emlangan odamda ijobiy IGRA standart tibbiy kuzatuvni talab qiladi.
Noaniq QuantiFERON natijasi nimani anglatadi?
Noto'g'ri QuantiFERON natijasi assay nazorati ishlamay qolganligini bildiradi, shuning uchun test TB infektsiyasini ijobiy yoki salbiy deb tasniflay olmaydi. Bu ko'pincha Mitogen-Nil 0,50 IU/mL dan past bo'lganda yoki Nil 8,0 IU/mL dan yuqori bo'lganda yuzaga keladi. Immunitet tanqisligi, o'tkir kasallik, limfopeniya va laboratoriya ishlovining kechikishi ko'pincha sabab bo'ladi. Shifokorlar ko'pincha tiklanishdan keyin testni takrorlaydilar yoki ta'sir xavfiga qarab terini tekshirish yoki mutaxassis baholashini tanlaydilar.
TB ga duch kelganimdan qancha muddat o'tgach IGRA testini topshirishim kerak?
IGRA sil kasalligiga duch kelgandan ko'p o'tmay amalga oshirilishi mumkin, ammo immunitet javobi rivojlanmaguncha salbiy natija ishonchli bo'lmasligi mumkin. CDC yaqin aloqadagi oxirgi ta'sirdan 8-10 hafta o'tgach salbiy testni takrorlashni tavsiya qiladi. Ijobiy natija, alomatlar yoki ko'krak qafasi tasviridagi anormalliklar takroriy oynani kutmasdan darhol baholashni talab qilishi kerak. Oxirgi ta'sirlanganlik sanasi birinchi marta aniqlangan sana sanasidan ko'ra foydaliroqdir.
IGRA salbiy natijasi sil kasalligini istisno qila oladimi?
Yaroqli salbiy IGRA sil kasalligi yuqtirish ehtimolini pasaytiradi, lekin faol sil yoki juda yaqinda yuqtirilganligini istisno qilmaydi. Soxta-negativ natijalar ekspozitsiyadan keyingi birinchi 2–8 hafta ichida va ilg'or OIV, og'ir kasallik yoki immunitetni bostiruvchi dorilarni qabul qilayotgan odamlarda ko'proq uchraydi. Salbiy natija doimiy yo'tal, isitma, tunda terlash yoki vazn yo'qotishni baholashni kechiktirmasligi kerak. Salbiy natija ishonchli deb hisoblanishidan oldin Mitogen nazorati etarli bo'lishi kerak.
Latent sil kasalligini davolashdan keyin ijobiy IGRA testini takrorlashim kerakmi?
Muvaffaqiyatli yashirin sil davolashdan so'ng ijobiy IGRA ko'pincha ijobiy bo'lib qoladi, shuning uchun uni takrorlash davolanishni tugatganligini isbotlamaydi va odatda davolash natijasini nazorat qilish uchun ishlatilmaydi. 0,35 IU/mL QuantiFERON ijobiylik chegarasi bakteriyalar tozalanib yoki nazoratga olingandan so'ng ham saqlanib qolishi mumkin bo'lgan immunitetni tan olishni aks ettiradi. Buning o'rniga, kuzatuv dori-darmonlarga rioya qilish, nojo'ya ta'sirlar va faol silni ko'rsatishi mumkin bo'lgan yangi alomatlarga qaratilgan. Kelajakda keraksiz takroriy skriningni oldini olish uchun shifokoringiz asl natijani hujjatlashtirishi mumkin.
Bugun AI asosidagi qon tahlilini tahlil qilishni oling
Kantesti’ga tezkor va aniq laboratoriya tahlili uchun ishonadigan butun dunyo bo‘ylab 2 milliondan ortiq foydalanuvchiga qo‘shiling. Qon tahlili natijalaringizni yuklang va soniyalar ichida 15,000+ biomarkerlarining to‘liq talqinini oling.
📚 Havola qilingan ilmiy tadqiqot nashrlari
Klein, T., Mitchell, S., & Weber, H. (2026). Ro'za tutgandan keyin diareya, najasda qora dog'lar va oshqozon-ichak trakti bo'yicha qo'llanma 2026. Kantesti AI tibbiy tadqiqoti.
Klein, T., Mitchell, S., & Weber, H. (2026). Ayollar salomatligi bo'yicha qo'llanma: Ovulyatsiya, menopauza va gormonal alomatlar. Kantesti AI tibbiy tadqiqoti.
📖 Tashqi tibbiy manbalar
Mazurek GH et al. (2010). Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection—United States, 2010. MMWR tavsiyalari va hisobotlari.
Jahon sog‘liqni saqlash tashkiloti (2021). WHO consolidated guidelines on tuberculosis: module 3: diagnosis—rapid diagnostics for tuberculosis detection. Jahon sog‘liqni saqlash tashkiloti.
⚕️ Tibbiy ogohlantirish
Ushbu maqola faqat ta’lim maqsadlari uchun mo‘ljallangan va tibbiy maslahatni anglatmaydi. Tashxis va davolash bo‘yicha qarorlar uchun har doim malakali sog‘liqni saqlash mutaxassisiga murojaat qiling.
E-E-A-T ishonch signallari
Tajriba
Shifokor boshchiligidagi laboratoriya talqin qilish ish jarayonlarini klinik ko‘rib chiqish.
Tajriba
Laboratoriya tibbiyoti biomarkerlarning klinik kontekstda qanday o‘zini tutishini yoritadi.
Vakolatlilik
Dr. Tomas Klein tomonidan yozilgan, Dr. Sarah Mitchell va Prof. Dr. Hans Weber tomonidan ko‘rib chiqilgan.
Ishonchlilik
Xavotirni kamaytirish uchun aniq keyingi qadamlar yo‘nalishlari bilan dalillarga asoslangan talqin.